Nelson, Van Denburg & Campbell Wealth Management Group, LLC Tg Therapeutics, Inc. Transaction History

Nelson, Van Denburg & Campbell Wealth Management Group, LLC

$2.42 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$13.02 - $21.3 $3,502 - $5,729	269 New	269 $4,000
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $274,983 - $642,411	-18,091 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$21.78 - $40.45 $84,375 - $156,703	3,874 Added 27.25%	18,091 $602,000
Q2 2021 Jul 27, 2021	BUY	$32.5 - $48.96 $462,052 - $696,064	14,217 New	14,217 $551,000

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

88.3M

Call Options Held

2.35M

Put Options Held

1.7M

Vanguard Group Inc Valley Forge, PA

15.4M
Shares

$455 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$336 Million
0.0% of portfolio
State Street Corp Boston, MA

9.09M
Shares

$269 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

3.58M
Shares

$106 Million
0.1% of portfolio
Geode Capital Management, LLC Boston, MA

3.21M
Shares

$94.7 Million
0.01% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nelson, Van Denburg & Campbell Wealth Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nelson, Van Denburg & Campbell Wealth Management Group, LLC with notifications on news.

Account